Skip to main content
Funded Studies

Patrick A. Howson, PhD

Chief Executive Officer at Junaxo Inc.

Location: Toronto ON Canada

Patrick Howson, PhD, is a founder and CEO of Junaxo Inc., a drug development company focused on novel therapies for Parkinson’s disease. His primary expertise lies in the outsourcing and managing research and development projects from medicinal chemistry through to Phase II clinical trials. Most recently he helped progress Cogane™ through a Phase II clinical trial in Parkinson’s disease. Dr. Howson is also a scientific associate at Toronto Western Hospital, University Health Network. Dr. Howson’s primary research interest is the development of disease-modifying therapies for neurodegenerative disorders. Dr. Howson holds a BSc (Hons.) in neuroscience from the University of Manchester, UK and a PhD in neurobiology from the University of Bristol.


Associated Grants

  • Development of Trehalose as a Disease-modifying Treatment for Parkinson’s Disease

    2013


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.